Lead Product(s) : Lansoprazole
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The Prevacid® brand and generic had U.S. sales of approximately $87 million MAT for the most recent twelve months ending in December 2020 according to IMS Health*.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 22, 2021
Lead Product(s) : Lansoprazole
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Aspirin,Avelumab,Lansoprazole
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : University of Manchester
Deal Size : Not Applicable
Deal Type : Not Applicable
Aspirin to be Trialled as Part of New Treatment for Aggressive Form of Breast Cancer
Details : Breast Cancer Now said successful results could lead to further clinical trials of aspirin and avelumab for incurable secondary triple negative breast cancer, which happens when cancer cells that started in the breast spread to other parts of the body.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 18, 2021
Lead Product(s) : Aspirin,Avelumab,Lansoprazole
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : University of Manchester
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
